Table 1. Selected ongoing trials involving non-VEGF mediated pathways of angiogenesis.
| Target | Drug | Malignancy | Phase | Trial |
|---|---|---|---|---|
| Angiopoietin/tie | ||||
| AMG 386 | Ovarian | III | NCT01281254 | |
| Ovarian | III | NCT01493505 | ||
| Ovarian | III | NCT01204749 | ||
| REGN-910 | Solid tumors | I | NCT01271972 | |
| Solid tumors | I | NCT01688960 | ||
| MEDI-3617 | Solid tumors | I | NCT01248949 | |
| Dll4-notch | ||||
| Demcizumab (OMP-21M18) | metastatic CRC | II | NCT01189942 | |
| Pancreatic | II | NCT01189929 | ||
| NSCLC | I | NCT01189968 | ||
| MEDI0639 | Solid tumors | I | NCT01577745 | |
| REGN-421 | Solid tumors | I | NCT00871559 | |
| RO4929097 | NSCLC | II | NCT01193868 | |
| Breast | I | NCT01071564 | ||
| Sarcoma | I/II | NCT01154452 | ||
| MK-0752 | Solid tumors | I | NCT01295632 | |
| Pancreatic | I/II | NCT01098344 | ||
| FGF (and VEGFR) | ||||
| Brivanib | HCC | III | NCT00858871 | |
| Metastatic CRC | I | NCT01046864 | ||
| Nintedanib | Metastatic CRC | II | NCT01362361 | |
| Endometrial | II | NCT01225887 | ||
| Thyroid | II | NCT01788982 | ||
| Ovarian | I | NCT01314105 | ||
| AZD4547 | Gastric | II | NCT01457846 | |
| NSCLC | I/II | NCT01824901 | ||
| Solid tumors | I | NCT00979134 | ||
| Dovitinib | Metastatic RCC | III | NCT01223027 | |
| Glioblastoma | II | NCT01753713 | ||
| Gastric | II | NCT01719549 | ||
| Metastatic breast | II | NCT01262027 | ||
| Castrate Resistant Prostate | II | NCT01741116 | ||
| TGF-β | ||||
| PF-03446962 | Urothelial | II | NCT01620970 | |
| Solid tumors | I | NCT00557856 | ||
| Solid tumors | I | NCT01337050 | ||
| TRC105 | Metastatic breast I/II | NCT01326481 | ||
| Glioblastoma | I/II | NCT01648348 | ||
| Metastatic RCC | II | NCT01727089 | ||
| Solid tumor | I | NCT01332721 | ||
| LY2157299 | Glioblastoma | II | NCT01582269 | |
| Pancreatic | I/II | NCT01373164 | ||
| HCC | II | NCT01246986 | ||
| HIF | ||||
| EZN-2968 | Solid tumors | I | NCT01120288 |